Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12188439 | 0.87 | AKT1 (0.47) | LMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL684404 | 0.87 | AKT1 (0.47) | LMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2738618 | 0.87 | ALDH1A1 (0.48) | LMNAALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL680766 | 0.87 | ALDH1A1 (0.48) | LMNAALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL16151918 | 0.84 | AKR1C3 (0.49) | SLC6A3 | |
| SCHEMBL681719 | 0.84 | ALDH1A1 (0.44) | LMNAALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL684403 | 0.83 | BRD4 (0.47) | LMNAALDH1A1SMN1; SMN2HPGDCYP3A4 | |
| SCHEMBL683279 | 0.83 | BRD4 (0.47) | LMNAALDH1A1SMN1; SMN2HPGDCYP3A4 | |
| SCHEMBL684107 | 0.83 | BRD4 (0.47) | LMNAALDH1A1SMN1; SMN2HPGDCYP3A4 | |
| SCHEMBL12390304 | 0.82 | ALDH1A1 (0.46) | LMNAALDH1A1HTTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349996-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8853199-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8846681-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | LMNA 1179/4885ALDH1A1 1144/4885HTT 1708/4885 |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | LMNA 3606/4885ALDH1A1 2098/4885HTT 2087/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | LMNA 3606/4885ALDH1A1 1715/4885HTT 2076/4885 |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | LMNA 3606/4885ALDH1A1 1715/4885HTT 2076/4885 |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | LMNA 3606/4885ALDH1A1 1715/4885HTT 2076/4885 |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | LMNA 3606/4885ALDH1A1 1715/4885HTT 2076/4885 |
| US-20140349996-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | LMNA 3017/4885ALDH1A1 2573/4885HTT 2644/4885 |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | LMNA 3017/4885ALDH1A1 2573/4885HTT 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.